Foundayo weight loss pill (orforglipron) is a once-daily oral GLP-1 medication from Eli Lilly, FDA-approved on April 1, 2026, for adults with obesity or overweight who have weight-related medical conditions. Unlike injectable GLP-1s such as Zepbound or Wegovy, Foundayo is a small-molecule tablet that can be taken any time of day with or without food or water. In the ATTAIN-1 clinical trial, adults on the highest dose (17.2 mg) lost an average of 27 pounds, roughly 12.4 percent of their starting body weight, over 72 weeks when combined with a reduced-calorie diet and regular exercise. It is the second oral GLP-1 pill approved in the United States after Novo Nordisk’s Wegovy pill.
What Is the Foundayo Weight Loss Drug?
The Foundayo weight loss drug contains orforglipron, a small-molecule (non-peptide) glucagon-like peptide-1 receptor agonist. It belongs to the same medication family as GLP-1 receptor agonists for weight loss like semaglutide and tirzepatide, but its chemistry is different. Because it is a small molecule rather than a peptide, the body absorbs it quickly through the digestive tract without needing to protect the drug from stomach acid. This is why patients do not need to fast or restrict water intake before taking it. Eli Lilly licensed orforglipron from Japan’s Chugai Pharmaceutical in 2018 for just $50 million upfront.
Eli Lilly’s New Weight-Loss Pill Foundayo Receives FDA Approval
Eli Lilly’s new weight loss pill Foundayo receives FDA approval on April 1, 2026, in what became the fastest new molecular entity approval since 2002. The FDA reviewed and cleared the application in only 50 days under the agency’s new Commissioner’s National Priority Voucher pilot program. The same headline is often reported as “Eli Lilly’s new weight-loss pill Foundayo receives FDA approval” and “FDA approves Eli Lilly’s daily oral weight loss pill Foundayo” across major medical outlets, all referring to the same milestone. The approval covers adults with a BMI of 30 or higher, or adults with a BMI of 27 or higher who also have at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes.
Eli Lilly’s New GLP-1 Weight-Loss Pill Foundayo Received FDA Approval: How It Works
Eli Lilly’s new GLP-1 weight-loss pill Foundayo received FDA approval based on its ability to mimic the natural GLP-1 hormone in the body. GLP-1 slows stomach emptying, sends fullness signals to the brain, and steadies blood sugar after meals. The result is smaller portions, fewer cravings, and less snacking between meals. The mechanism is similar to how injectable drugs work for Ozempic in type 2 diabetes and weight loss, but Foundayo delivers the effect through a daily pill. Since it is a small molecule, it does not have the strict fasting rules that peptide-based oral GLP-1s require, which makes it easier to fit into everyday routines.
Eli Lilly’s New Oral Weight-Loss Pill Foundayo Receives FDA Approval: Clinical Trial Results
Eli Lilly’s new oral weight-loss pill Foundayo receives FDA approval based on the ATTAIN-1 and ATTAIN-2 Phase 3 trials, which studied more than 3,000 adults. In ATTAIN-1, adults without diabetes who took the 17.2 mg dose lost an average of 11.1 percent of body weight (24.9 pounds) at 72 weeks. Those who completed the full protocol lost an average of 27.3 pounds (12.4 percent). Participants on 9 mg lost 8.3 percent, and those on 5.5 mg lost 7.4 percent. In the diabetes trial (ATTAIN-2), adults with type 2 diabetes on the highest dose lost 9.6 percent (21.2 pounds). Results appeared gradually across the 72-week period, similar to the pattern seen with Ozempic weight loss over time.
Foundayo Weight Loss: Realistic Results You Can Expect
When people ask about Foundayo weight loss results (sometimes misspelled as “foundaya weight loss”), the honest answer is that outcomes depend heavily on dose, adherence, diet quality, and physical activity. Trial averages ranged from about 5 pounds on placebo to 27 pounds on the highest dose over 18 months. Most patients start seeing changes around week 8 to 12, with steady loss continuing through month 12. The final 3 to 6 months are usually about plateau management rather than dramatic new losses. Foundayo is not designed for rapid or cosmetic weight loss. It is a long-term treatment for chronic weight management, and stopping the medication often leads to regain, similar to what happens when patients stop taking Ozempic.
Foundayo for Weight Loss: Who Should Consider This Pill?
Foundayo for weight loss is FDA-approved for adults with a BMI of 30 or higher, and for adults with a BMI of 27 to 29.9 who have at least one weight-related medical condition. Qualifying conditions include type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, and cardiovascular disease. It is not approved for cosmetic weight loss or for anyone whose BMI falls below these thresholds. Patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 should not take Foundayo. Pregnant women and those breastfeeding are also excluded, and Foundayo should never be combined with other GLP-1 medications.
Foundayo Weight Loss Medication: Dosage and How to Take It
The Foundayo weight loss medication comes in tablet form with doses of 0.8 mg, 1.6 mg, 2.4 mg, 5.5 mg, 9 mg, and 17.2 mg. Treatment starts at 0.8 mg once daily for the first four weeks, then increases in monthly steps to the maintenance dose based on tolerance and response. The 17.2 mg tablet is considered the highest maintenance dose. Foundayo can be taken any time of day, with or without food or water. This flexibility is a major advantage over other oral GLP-1s. If a dose is missed and it has been more than 12 hours, patients should skip it and resume the regular schedule the next day. The gradual dose escalation is designed to reduce nausea and other digestive side effects.
Foundayo Weight Loss Pills: Side Effects and Safety
The most common Foundayo weight loss pills side effects reported in trials include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, fatigue, gastroesophageal reflux, flatulence, and hair loss. Most side effects are mild to moderate and improve after the first few weeks as the body adjusts. Foundayo carries a boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma, based on animal studies. Other serious risks include pancreatitis, gallbladder problems, kidney injury from dehydration, and low blood sugar (especially in patients also taking insulin or sulfonylureas). Muscle loss during weight loss is another consideration, similar to the concerns discussed in preventing muscle loss on Ozempic.
Foundayo Weight Loss Pill Cost: What You Will Pay
The Foundayo weight loss pill cost varies based on insurance coverage and dose. Cash-pay patients pay around $149 per month for the lowest dose and up to $349 per month for higher doses through LillyDirect. With commercial insurance and Eli Lilly’s Foundayo Savings Card, eligible patients may pay as little as $25 per month. Starting July 1, 2026, eligible Medicare Part D members may access Foundayo for approximately $50 per month through Lilly’s Medicare GLP-1 Bridge program. Foundayo is priced similarly to tirzepatide cost and generally more accessible than semaglutide without insurance, especially for cash-pay patients.
Foundayo Weight Loss Pill Price with Insurance and Cash
The Foundayo weight loss pill price with insurance is one of the more accessible entry points in the GLP-1 market. Commercial insurance holders using the savings card can get monthly pricing as low as $25 (or $1 per day). Without insurance, cash-pay starts at $149 per month for the 0.8 mg starter dose. Higher maintenance doses can reach $299 to $349 per month at retail. Amazon Pharmacy displays real-time pricing and automatically applies manufacturer coupons at checkout, so patients see the actual out-of-pocket amount before ordering. For comparison, injectable GLP-1s like Ozempic and Wegovy without insurance often cost $900 to $1,300 per month at cash prices.
Eli Lilly’s New Foundayo Weight-Loss Pill Available Via Amazon
Eli Lilly’s new Foundayo weight-loss pill available via Amazon Pharmacy makes access much easier than traditional prescription channels. As of April 9, 2026, Amazon Pharmacy offers same-day delivery of Foundayo in nearly 3,000 U.S. cities and towns, with plans to expand to 4,500 locations by year-end. In select One Medical clinic locations across California, patients can pick up Foundayo from an in-clinic kiosk minutes after their consultation. Amazon Pharmacy fulfills prescriptions from LillyDirect and partners like WeightWatchers and GoodRx. Because Foundayo is a room-temperature tablet, it does not need cold-chain shipping the way injectable GLP-1s do, which simplifies delivery and reduces cost.
Foundayo vs Zepbound Weight Loss: Which Is Right for You?
The Foundayo vs Zepbound weight loss comparison comes down to convenience versus potency. Zepbound (tirzepatide injection) produces higher average weight loss of about 21 percent, while Foundayo averages 11 to 12.4 percent at the highest dose. Both are from Eli Lilly. Zepbound requires weekly self-injection and refrigeration. Foundayo is a daily oral tablet with no storage or timing restrictions. For patients uncomfortable with needles, dealing with travel restrictions, or looking for a lower-cost entry into GLP-1 therapy, Foundayo makes sense. For those with higher BMI or aggressive weight loss goals under medical supervision, Zepbound may still be the stronger choice. A similar comparison exists between Mounjaro and Zepbound since both share the same active ingredient.
Eli Lilly Weight Loss Pill Foundayo: When It Isn’t Enough
The Eli Lilly weight loss pill Foundayo works well for many people, but medication alone is not a full solution for everyone. For adults with a BMI above 40, or above 35 with serious weight-related conditions like uncontrolled diabetes or severe sleep apnea, bariatric surgery consistently delivers more durable weight loss (typically 25 to 30 percent of body weight) and stronger metabolic improvement than any GLP-1 medication alone. At BodEvolve Bariatric, our team evaluates patients across the Dallas-Fort Worth metro for the full range of options, from medical weight management to gastric sleeve surgery and gastric bypass. We see patients at our offices in Arlington, Richardson, Dallas, and Texarkana, and offer a comprehensive GLP-1 weight loss program for patients who prefer non-surgical treatment. Book a consultation to find out which option fits your goals.
